BIONTECH SE SPON. ADRS 1
Commented by Nico Popp on October 16th, 2020 | 12:19 CEST
CureVac, BioNTech, Valeo Pharma: Where is there still potential?
The race for vaccines against Covid-19 is fierce. Every day there are new water level reports - from setbacks to breakthroughs, everything is there. The Tübingen-based Company CureVac recently started its phase study IIa in Peru and Panama. Around 700 people are taking part in it. The study aims to find suitable dosages for the vaccine. To this end, test persons are vaccinated twice within 28 days. Other competitors, such as BioNTech, are already testing their vaccine on more volunteers. BioNTech recently started its phase III study in South Africa and is testing the vaccine on more than 40,000 people worldwide.
Read
Commented by Stefan Feulner on October 15th, 2020 | 13:16 CEST
Bayer, Triumph Gold, BioNTech - decisive phase!
Almost everyone knows the philosophies proclaimed by the great and wise stock market gurus. “Never try catch a falling knife" or "buy on the sound of cannons, sell on the sound of trumpets”. What is true? In the case of Bayer, after the Monsanto disaster, possibly higher than planned fines and a cracking profit warning, one might think that everything has already been priced in. However, it is still not known how and when the Monsanto disaster will end. The fact is, there are other, more appealing papers at the moment ...
Read
Commented by Stefan Feulner on October 14th, 2020 | 11:40 CEST
BioNTech, BIGG, Bitcoin - The traffic lights are green!
A trend is present when the price of security tends to move in a specific direction, even under fluctuation. To play this trend correctly and to make more significant price gains, one should recognize the signals of a trend reversal. With Bitcoin & Co., this could soon be the case. The stabilization phase is still underway, but buying pressure has increased in the last few days. Companies that have a unique position in the crypto market could benefit from this.
Read
Commented by Stefan Feulner on October 9th, 2020 | 12:37 CEST
BioNTech, Barrick Gold, Velocity Minerals - Golden Times!
No! The end of the gold price increase has yet to be reached. The problems, which have become even more acute in recent months due to the pandemic, will not disappear overnight. It is understandable that the price of the precious metal will briefly collapse because "Big Donald" is saluting himself, or the helicopter pilot who brought him safely back to the White House after his short, three-day intermezzo in the military hospital. He wants to show that he has quickly left Corona behind him. However, among his many headwinds, the President now faces the US election, the still high number of Covid-19 cases in the US, the rapidly increasing national debt, and the unchecked money printing of the central banks. At least in terms of case numbers, there is positive news from BioNTech. The Corona vaccine candidate, developed by the Mainz-based company, is entering the approval phase.
Read
Commented by Mario Hose on September 29th, 2020 | 10:51 CEST
BioNTech, Bayer, Valeo Pharma: Share price jump ahead of quarterly results
Investors' expectations of developments can drive the share price. When it comes to solving a problem or creating needs, the interest of the capital market is particularly high. Things get exciting for investors when the business model offers the possibilities of scalability. Attractive investment opportunities can be created in the fields of health and medicine, which offer extraordinary return opportunities.
Read
Commented by Mario Hose on September 28th, 2020 | 10:15 CEST
BioNTech, NEL ASA, Silver Viper: Profit lies in purchasing
As is well known, timing is of paramount importance for the stock market. Investors who look to take a position always look for the best possible entry point. Rarely do even experienced stock market traders succeed in hitting the low point before the price rises. In connection with the current Corona Pandemic and the uncertainties as to how the course of a possible second wave of infection will develop, there have already been considerable price fluctuations and entry opportunities on the stock markets in recent weeks.
Read
Commented by Mario Hose on September 23rd, 2020 | 09:05 CEST
BioNTech, CureVac, or Valeo Pharma: who brings the highest return to shareholders?
When the Corona Pandemic started in November 2019 in Wuhan, China, nobody could have guessed the extent of the disease. Socially, economically and politically, Covid-19 has turned the world upside down. With increasing knowledge in dealing with the coronavirus, people around the globe are trying to come to terms with the new state of affairs - as best they can. On the stock market, there are numerous opportunities for investors to participate in further development in the fight against serious diseases.
Read
Commented by Mario Hose on September 18th, 2020 | 06:00 CEST
BioNTech, CureVac, EXMceuticals - reaching their goal with government support
In the fight against the spread of the Corona Pandemic, a great deal of commitment is required from companies. This situation also offers the opportunity to rethink and change existing work processes and procedures. Product ranges are being expanded and new possibilities and active ingredients are being sought to combat Covid-19. Above all, the common good of all is the primary focus of political institutions and for this reason they are not letting research-based companies down and are attracting them with special permits and subsidies. Ultimately, everyone around the world will likely benefit from this.
Read
Commented by Mario Hose on September 11th, 2020 | 09:59 CEST
BioNTech, CureVac, Valeo Pharma - Growth after capital injection
Anyone working in the medical sector knows that the development of therapies and products usually costs a lot of time and especially a lot of money. In the race against the spread of the current Corona pandemic, there are major changes in the industry, because whoever comes to the market with a product first is de facto guaranteed high sales and profits. However, there is not much time left for the development of a vaccine against Covid-19 and to reduce the economic damage, researching companies have virtually unlimited amounts of money available. Whoever finds a solution against Covid-19 will certainly have the right team in the starting blocks in the fight against the subsequent Corona viruses.
Read
Commented by Mario Hose on September 1st, 2020 | 11:56 CEST
BioNTech, CureVac, Valeo Pharma - COVID-19 wakes up the industry
In the past, people have accepted that it usually takes about ten years to get a vaccine on the market. Careful testing with proof of success is required for a preparation to receive approvals. Since COVID-19, the pressure to develop has increased dramatically and also the potential to close a lucrative deal, because a lot is at stake for politics and economy. The necessary tests are carried out at great expense in order not to endanger human life through a vaccination, but to protect it. There are great opportunities for investors.
Read